Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Cash from Investing Activities (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Cash from Investing Activities for 4 consecutive years, with $24.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities fell 37.06% to $24.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $115.7 million, a 226.24% increase, with the full-year FY2024 number at $47.5 million, down 22.33% from a year prior.
  • Cash from Investing Activities was $24.7 million for Q3 2025 at Century Therapeutics, down from $32.5 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $39.2 million in Q3 2024 to a low of -$44.0 million in Q1 2022.
  • A 4-year average of $12.0 million and a median of $18.6 million in 2023 define the central range for Cash from Investing Activities.
  • Biggest YoY gain for Cash from Investing Activities was 829.55% in 2024; the steepest drop was 585.57% in 2024.
  • Century Therapeutics' Cash from Investing Activities stood at -$4.3 million in 2022, then surged by 535.36% to $18.6 million in 2023, then skyrocketed by 64.52% to $30.6 million in 2024, then dropped by 19.39% to $24.7 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Cash from Investing Activities are $24.7 million (Q3 2025), $32.5 million (Q2 2025), and $27.9 million (Q1 2025).